Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
  • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
  • A23L2/52—Adding ingredients
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/18—Antioxidants, e.g. antiradicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/12—Ophthalmic agents for cataracts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Definitions

• the present invention relates to an antioxidant that can be used as a medicine, food and drink, a food additive, a skin external preparation, and the like.
• Oxidative stress is defined as a state in which the production of reactive oxygen species (ROS) in the living body and the antioxidant defense mechanism are unbalanced and leaning toward oxidation. That is, excessive production of ROS or a decrease in antioxidant capacity leads to oxidative stress.
• ROS oxidizes low density lipoproteins (LDL) of lipids, particularly phospholipids, to produce lipid peroxides and oxidized LDL, and oxidatively denatures and inactivates proteins to cause oxidative damage to DNA. Therefore, oxidative stress is involved in the development of many diseases such as arteriosclerosis, cancer, various lifestyle-related diseases, Alzheimer's disease, and Parkinson's disease by damaging cells and tissues and impairing biological functions. Is promoted (for example, Non-Patent Document 1).
• ROS is easily produced by stimulation of environmental factors such as ultraviolet rays.
• ROS in the skin damages cells by destroying biological tissues such as collagen, and causes skin symptoms such as wrinkles, reduced elasticity, inflammation, and pigmentation.
• ROS is also known to oxidize scalp proteins and lipids and cause hair loss (for example, Patent Documents 1 and 2).
• lipid peroxide is known to cause vascular disorders, liver dysfunctions, cataracts, etc., when the concentration of lipid peroxide increases in the blood itself or its oxidative degradation products directly act on nucleic acids and proteins. Yes. Furthermore, it is considered to cause arteriosclerosis because it causes damage to vascular endothelial cells, increased platelet aggregation, and formation of foam cells. For example, it is known that early lesions of arteriosclerosis are caused by oxidized low density lipoprotein (LDL), and the simplest way to know the oxidation of LDL is known to be measuring lipid peroxides. (For example, Non-Patent Document 2).
• LDL low density lipoprotein
• vitamin E As antioxidants derived from natural products, vitamin E, vitamin C, neutral fractions of plant extracts of the genus Helichrysum (for example, Patent Document 1), extracts of Euphorbia (for example, Patent Document 2), etc. It has been known.
• Patent Document 9 discloses a lipid peroxide production inhibitor as a skin external preparation containing steroid glycoside and / or triterpenoid glycoside and glycosphingolipid.
• antioxidants such as BHT (3,5-tert-butyl-4-hydroxytoluene) and BHA (2,3-tert-butyl-hydroxyanisole) have been developed to suppress oxidation of lipids and the like.
• BHT 3,5-tert-butyl-4-hydroxytoluene
• BHA 2,3-tert-butyl-hydroxyanisole
• a hyperglycemia improving agent pancreatic function improving agent, insulin resistance improving agent and visceral fat accumulation inhibitor containing 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient Agents are known (Patent Document 10, Patent Document 11, Patent Document 12 and Patent Document 13, respectively).
• An object of the present invention is to provide an antioxidant that is highly safe, suppresses oxidation of biological components, particularly lipids, and can be used as a medicine, food and drink, food additive, skin external preparation, and the like.
• an object of the present invention is to provide a medicine, food and drink, etc. for inhibiting lipid peroxide production, which effectively inhibits production of lipid peroxide in blood.
• a first invention for solving the above-described problem is an antioxidant (hereinafter referred to as “antioxidant of the present invention”) containing a compound represented by the following chemical formula (1) as an active ingredient, and the following ( 1) to (6) are preferred forms.
• the second invention for solving the above problem is a method for producing an antioxidant, comprising a step of blending a compound represented by the chemical formula (1) as an active ingredient.
• 1st invention contains the form of the pharmaceutical for lipid-lipid-production suppression containing the compound shown by Chemical formula (1) as an active ingredient.
• This form has the following (7) as a preferred form. (7) Containing at least 0.0001% by mass of the compound represented by the chemical formula (1).
• 2nd invention includes the form of the manufacturing method of the pharmaceutical for lipid-peroxide production suppression including the process of mix
• 1st invention contains the form of the food-drinks for lipid peroxide production suppression containing the compound shown by Chemical formula (1) as an active ingredient.
• the following (8) to (11) are preferable forms.
• 2nd invention contains the form of the manufacturing method of the food-drinks for lipid peroxide production
• 1st invention contains the form of the food additive for lipid peroxide production suppression containing the compound shown by Chemical formula (1) as an active ingredient. This form makes the following (12) and (13) a preferable form. (12) Further containing an emulsifier, (13) Containing at least 0.001% by mass of the compound represented by the chemical formula (1).
• 2nd invention includes the form of the manufacturing method of the food additive for lipid peroxide production suppression including the process of mix
• 3rd invention which solves the said subject is use of the compound shown by Chemical formula (1) in manufacture of an antioxidant.
• the third invention includes the following forms. (14) Use of a composition containing at least 0.0001% by mass of the compound represented by the chemical formula (1) in the production of an antioxidant.
• 3rd invention includes the form of use of the compound shown by Chemical formula (1) in manufacture of the pharmaceutical for lipid peroxide production
• 3rd invention includes the form of use of the compound shown by Chemical formula (1) in manufacture of the food-drinks for lipid peroxide production
• 3rd invention also includes the form of use of the compound shown by Chemical formula (1) in manufacture of the food additive for lipid peroxide production
• the fourth invention for solving the above-mentioned problem is a compound represented by the chemical formula (1) used for antioxidant. Moreover, it is preferable that the said compound is used in order to suppress the oxidation of a lipid, and it is preferable to be used in order to suppress the production
• 4th invention contains the form of the composition containing the compound shown by Chemical formula (1) used for antioxidant.
• the preferable form of this composition is as follows. (18) A composition comprising a compound represented by the chemical formula (1) and an emulsifier. (19) A composition containing at least 0.0001% by mass of the compound represented by the chemical formula (1).
• the fifth invention for solving the above-mentioned problem is a method for treating or preventing a disease or symptom contributed by oxidation, comprising administering a compound represented by the chemical formula (1) to a subject in need of antioxidant. Moreover, 5th invention makes the following (20) a preferable form. (20) Administering a composition containing at least 0.0001% by mass of the compound represented by the chemical formula (1).
• 6th invention which solves the said subject is the method of providing antioxidant activity to food / beverage products, Comprising: The density
• the method includes a step of blending the compound into a food or drink.
• 7th invention which solves the said subject is the method of enhancing the antioxidant activity of the food / beverage products containing the compound shown by Chemical formula (1), Comprising: The density
• the antioxidant of the present invention can be used in various forms such as pharmaceuticals, foods and drinks, food additives, and external preparations for skin, and suppresses oxidation of biological components, particularly lipid oxidation.
• the medicament of the present invention can be safely administered and effectively suppresses the oxidation of biological components, particularly the production of lipid peroxide in the blood.
• the food / beverage products of this invention can be ingested safely, and suppress effectively the oxidation of a biological component, especially the production
• the food additive of this invention is suitable for manufacturing the said food / beverage products, or preventing the oxidation of the component of food / beverage products.
• the skin external preparation of this invention can be apply
• 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol which is an active ingredient of the antioxidant of the present invention, can be produced by chemical synthesis.
• the antioxidant of the present invention can be easily produced.
• the active ingredient of the antioxidant of the present invention is easily produced from a lily family plant, for example, a plant such as Aloe barbadensis Miller, which has been confirmed to be safe from dietary experience and is easily available. Therefore, according to the production method of the present invention, the antioxidant of the present invention can be produced easily.
• the antioxidant of the present invention contains 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.
• the compound which is an active ingredient of the antioxidant of the present invention is a compound having a structure represented by the following chemical formula (1), that is, 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-ene -3-ol.
• the compound of the present invention has a structure in which the hydroxyl group at the 3-position of 4-methylergost-7-en-3-ol and the hydroxyl group at the 1-position of D-glucose are dehydrated and condensed.
• the compound of the present invention can be obtained by, for example, synthesizing 4-methylergost-7-en-3-ol according to the supplement data of PLOS BIOLOGY, No. 2, page e280, and then condensing D-glucose. Can be manufactured.
• 4-Methylergost-7-en-3-ol can also be obtained by extraction and purification from plants.
• the molecular weight, structure, etc. of the compound produced as described above can be determined or confirmed by, for example, a mass spectrum (MS) method and a nuclear magnetic resonance spectrum (NMR) method.
• MS mass spectrum
• NMR nuclear magnetic resonance spectrum
• 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol may be a pharmaceutically acceptable salt.
• Pharmaceutically acceptable salts include both metal salts (inorganic salts) and organic salts, such as “Remington's Pharmaceutical Sciences, 17th edition, 1985, page 1418”. What is published in is illustrated.
• inorganic acid salts such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and sulfate, malate, maleate, fumarate, tartrate
• Organic salts such as succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, pamoate, salicylate, and stearate are included without limitation.
• it can also be set as salts with amino acids, such as metals, such as sodium, potassium, calcium, magnesium, and aluminum, and a lysine.
• solvates such as hydrates of the above compounds or pharmaceutically acceptable salts thereof can be used.
• the antioxidant of the present invention contains 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.
• the content of 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol in the antioxidant of the present invention can be appropriately selected depending on the target disease and administration subject. , Preferably at least 0.0001% by weight, more preferably at least 0.001% by weight, even more preferably at least 0.005% by weight, particularly preferably at least 0.01% by weight.
• the upper limit of the amount in the medicament of the present invention is not particularly limited, but 90% by mass or less, preferably 70% by mass or less, more preferably 50% by mass or less is exemplified.
• the antioxidant of the present invention can be used in the form of pharmaceuticals, foods and drinks, food additives, skin external preparations and the like.
• the antioxidant of the present invention in the form of using the antioxidant of the present invention as a medicament (referred to as “medicament of the present invention”), it can be administered orally or parenterally to mammals including humans.
• the medicament of the present invention can be used for preventing and / or treating a disease or symptom involving the oxidation of biological components such as lipids, particularly the production of lipid peroxide.
• diseases or symptoms include arteriosclerosis, stroke, angina pectoris, myocardial infarction, liver dysfunction, cirrhosis, hepatitis, retinopathy, cataract, Alzheimer's disease, Parkinson's disease, allergic disease, cancer, rough skin
• diseases or symptoms include arteriosclerosis, stroke, angina pectoris, myocardial infarction, liver dysfunction, cirrhosis, hepatitis, retinopathy, cataract, Alzheimer's disease, Parkinson's disease, allergic disease, cancer, rough skin
• examples include aging, atopic dermatitis, pigmentation such as stains and freckles, wrinkles and decreased elasticity, hair loss, rheumatoid arthritis, tissue disorders such as Behcet's disease, stiff shoulders, coldness, and the like.
• the medicament of the present invention has a remarkable effect particularly on the prevention and / or treatment of arteriosclerosis, angina pectoris, and myocardial infarction.
• the pharmaceutical of this invention is useful with respect to the person
• the form of the pharmaceutical preparation of the present invention is not particularly limited and can be appropriately selected depending on the therapeutic purpose and usage. Specific examples include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, syrups, suppositories, injections, ointments, patches, eye drops, nasal drops, etc. it can.
• the administration time of the medicament of the present invention is not particularly limited, and can be appropriately selected according to the target disease.
• the dosage is preferably determined according to the preparation form, usage, patient age, sex, other conditions, the degree of symptoms, and the like.
• the dosage of the medicament of the present invention is appropriately selected depending on the usage, patient age, sex, disease severity, other conditions, and the like.
• the range is preferably 0.001 to 50 mg / kg / day, more preferably 0.01 to 1 mg / kg / day.
• one of the preferred forms of the medicament of the present invention is that the compound represented by the chemical formula (1) is administered preferably at 0.001 to 50 mg / kg / day, more preferably 0.01 to 1 mg / kg / day. It is a medicine used as follows.
• the medicament of the present invention may contain additives commonly used in medicaments for inhibiting lipid peroxide production.
• additives include excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, diluents, surfactants, solvents for injections, and the like.
• the medicament of the present invention can be used for preventing or treating diseases and symptoms as long as the antioxidant action of 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol is not impaired.
• it may contain other ingredients having an action to improve and / or prevent arteriosclerosis, stroke, liver dysfunction and the like.
• the medicament of the present invention can be produced by blending 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient in a pharmaceutical carrier.
• the medicament of the present invention can be produced, for example, by formulating the compound together with the aforementioned additives.
• the medicament of the present invention is an extract obtained by extracting and concentrating a fraction containing the compound from a known plant containing the compound or a part thereof or a crushed product thereof using an organic solvent or hot water. It can also be manufactured by formulating a product with the above-mentioned additives.
• the medicament of the present invention uses, for example, an extract obtained by crushing and liquefying a mesophyll (transparent gel) portion not containing aloe vera leaf bark using a homogenizer or the like, and extracting with an organic solvent or hot water. Can be manufactured.
• examples of the organic solvent include alcohols such as methanol, ethanol and butanol; esters such as methyl acetate, ethyl acetate, propyl acetate and butyl acetate; ketones such as acetone and methyl isobutyl ketone; ethers such as diethyl ether and petroleum ether; Hydrocarbons such as hexane, cyclohexane, toluene and benzene; halogenated hydrocarbons such as carbon tetrachloride, dichloromethane and chloroform; heterocyclic compounds such as pyridine; glycols such as ethylene glycol; polyalcohols such as polyethylene glycol; acetonitrile and the like Nitrile solvents, and mixed solutions of these solvents.
• alcohols such as methanol, ethanol and butanol
• esters such as methyl acetate, ethyl acetate, propyl acetate and butyl acetate
• solvents may be anhydrous or may be in a water-containing state.
• an ethyl acetate / butanol mixed solution (3: 1) or a chloroform / methanol mixed solution (2: 1) is preferable.
• an extraction method a method used for extraction of normal plant components can be used. Usually, 1 to 300 parts by mass of an organic solvent is used per 1 part by mass of a fresh plant or a dried plant, and the mixture is heated to reflux at a temperature below the boiling point of the solvent while stirring or shaking, or ultrasonically extracted at room temperature. Is mentioned.
• the extract can be separated from insolubles by an appropriate method such as filtration or centrifugation to obtain a crude extract.
• the crude extract can be purified by various types of chromatography, such as normal phase or reverse phase silica gel column chromatography.
• the medicament of the present invention may be used alone, but can also be used in combination with a known prophylactic / therapeutic agent for the disease. By using in combination, the preventive / therapeutic effect of the disease can be enhanced.
• the prophylactic / therapeutic agent for the above-mentioned diseases to be used in combination may be contained as an active ingredient of the medicament of the present invention, or it is not contained in the medicament of the present invention, but is combined as a separate drug product and combined at the time of use. It may be a type kit.
• the medicament of the present invention exhibits an excellent lipid peroxide production inhibitory effect due to the antioxidant action of 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol.
• the food and drink of the present invention In the form of using the antioxidant of the present invention as a food or drink (referred to as “the food or drink of the present invention”), the food or drink is a risk of a disease or symptom involving the oxidation of biological components such as lipids, particularly the production of lipid peroxide. Or can be used to prevent such diseases or symptoms.
• the food / beverage product of the present invention contains 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.
• “food and beverage” includes food and beverages consumed by humans and feeds consumed by animals other than humans.
• the amount of 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol in the food or drink of the present invention is appropriately set depending on the form of the food or drink, but is preferably at least 0.0001. % By weight, more preferably at least 0.001% by weight, even more preferably at least 0.005% by weight, particularly preferably at least 0.01% by weight. Moreover, especially the upper limit of the said quantity in the food / beverage products of this invention is although it does not restrict
• the amount of the compound in the food or drink of the present invention is in the range of 0.001 to 50 mg / kg / day, more preferably 0.01 to 1 mg / kg / day, depending on the form of the food or drink. It is also possible to make the amount suitable for the above. Accordingly, one of the preferred forms of the food or drink of the present invention is a food or drink used to take the compound preferably at 0.001 to 50 mg / kg / day, more preferably 0.01 to 1 mg / kg / day. It is a product.
• the food or drink of the present invention preferably further contains an emulsifier.
• an emulsifier is not particularly limited as long as it can be used for food.
• the food-drinks containing an emulsifier have the high dispersibility of the compound shown by Chemical formula (1), it is excellent in the stability of an effect.
• a food / beverage product with excellent storage stability in which deterioration due to lipid oxidation is suppressed is provided.
• You can also The content of the compound is as described above.
• it is also preferable that such food and drink is an emulsified food.
• Food / beverage products containing fats and oils include edible oil, dressing, mayonnaise, butter, margarine, cream and the like.
• a form containing an emulsifier is preferable. Preferred emulsifiers are as described above.
• the food or drink of the present invention is preferably a functional food or drink.
• the “functional food or drink” means a food on which a disease prevention effect or a disease risk reduction effect is directly or indirectly displayed. For example, currently, foods sold in the form of food for specified health use and health supplement foods are listed in Japan.
• Examples of the form of the food and drink of the present invention include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit juice drinks, lactic acid bacteria drinks (including concentrated concentrates and powders for preparation of these drinks); ice cream, ice sherbet, shaved ice, etc.
• Noodles such as buckwheat, udon, harusame, gyoza skin, cucumber skin, Chinese noodles, instant noodles, etc.
• Confectionery such as confectionery; processed fishery and livestock products such as kamaboko, ham, sausage; dairy products such as processed milk, milk drinks, fermented milk, butter; side dish, bread; other enteral nutrition food, liquid food, childcare Milk and sports drinks.
• the functional food or drink is in the form of granules, tablets, or liquid because it is easy for the intaker to grasp the intake amount of the active ingredient.
• the food / beverage products of the present invention are preferably in a form with indications of uses “for antioxidants”, “for lipid lipid inhibition”, and “for lipid peroxide production inhibition”. That is, the food / beverage product of the present invention is, for example, 3-O- ⁇ -D-glucopyranosyl-4-methylergosto-7-en-3-ol, which is used for “inhibition of lipid peroxide production”. It is preferable to sell as a food or drink for containing lipid peroxide as an active ingredient.
• the “display” includes all displays having a function of informing the consumer of the use.
• any display capable of recalling / analyzing the use corresponds to the “display” regardless of the purpose of display, the content of the display, the object / medium to be displayed, and the like.
• the “display is attached” means that there is a display act of associating and recognizing the display and the food or drink (product). It is preferable that the display act is one in which the consumer can directly recognize the application.
• the application to the product relating to the food and drink of the present invention or the packaging of the product, the use of the advertisement to the product, the price list or transaction documents (including those provided by electromagnetic methods) Can be exemplified.
• the displayed content is a display approved by the government or the like (for example, a display that is approved based on various systems determined by the government and is performed in a mode based on such approval).
• the display of health foods, functional foods and drinks, enteral nutritional foods, special purpose foods, health functional foods, foods for specified health, nutritional functional foods, quasi drugs, and the like can be exemplified.
• a display approved by the Ministry of Health, Labor and Welfare for example, a display approved by a food system for specific health use or a system similar thereto can be exemplified.
• Examples of the latter can include a display as a food for specified health use, a display as a condition specific food for specified health use, a display that affects the structure and function of the body, a display for reducing disease risk, etc.
• a display as a food for specified health use a display as a condition specific food for specified health use
• a display that affects the structure and function of the body a display for reducing disease risk, etc.
• the display can be listed as a typical example.
• the wording indicating the use is not limited to the words “for antioxidation”, “for lipid oxidation inhibition”, “for lipid peroxide production inhibition”, and other words, Antioxidant action or effect, words expressing action or effect of inhibiting lipid peroxide production, ROS, action or effect for preventing disease or symptom involving lipid peroxide, action for reducing risk of occurrence of the disease or symptom, or Needless to say, any word including an expression relating to the effect is included in the scope of the present invention.
• the food / beverage products of this invention include the display of the said active ingredient in addition to the display of the said use, Furthermore, the display which shows the relevance of the said use and the said active ingredient.
• the food / beverage product of the present invention can be produced by blending 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.
• the food / beverage products of this invention can be manufactured by mixing the said compound with food-drinks raw material, and processing, for example.
• the food / beverage products of this invention can also be manufactured by processing the extract obtained by extraction using hot water or various solvents from the well-known plant containing the said compound with a food / beverage material raw material. .
• the specific method for obtaining the extract is as exemplified in the section of “medicament of the present invention”.
• the active ingredient 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-ene- 3-ols include, for example, saccharides such as lactulose, maltitol, and lactitol, and other saccharides such as dextrin and starch; proteins such as gelatin, soybean protein, and corn protein; amino acids such as alanine, glutamine, and isoleucine It is preferably formulated together with polysaccharides such as cellulose and gum arabic; oils and fats such as soybean oil and medium chain fatty acid triglycerides.
• saccharides such as lactulose, maltitol, and lactitol, and other saccharides such as dextrin and starch
• proteins such as gelatin, soybean protein, and corn protein
• amino acids such as alanine, glutamine, and isoleucine It is preferably formulated together with polysaccharides such as cellulose and gum arabic; oils and fats such as soybean oil and medium
• the food additive In the form in which the antioxidant of the present invention is used as a food additive (referred to as “food additive of the present invention”), the food additive is used as a disease that involves oxidation of biological components such as lipids, particularly lipid peroxides. In order to reduce the risk of symptoms or prevent such diseases or symptoms, it can be added to food and drink.
• the food additive of the present invention can be used by adding to a food or drink in order to suppress oxidation of components in the food or drink, for example, lipids.
• the food additive of the present invention is particularly suitable for addition to foods and drinks containing fats and oils, preferably foods and drinks mainly comprising fats and oils.
• the example of the food / beverage products containing fats and oils is as having mentioned by the term of the "food / beverage products of this invention".
• the food additive of the present invention contains 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.
• the amount of 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol in the food additive of the present invention is appropriately set, but is preferably at least 0.001% by mass, more preferably Is at least 0.01% by weight, more preferably at least 0.05% by weight, particularly preferably at least 0.1% by weight.
• the upper limit of the amount in the food additive of the present invention is not particularly limited, but is 90% by mass or less, preferably 70% by mass or less, more preferably 50% by mass or less.
• the food additive of the present invention preferably further contains an emulsifier.
• an emulsifier is not particularly limited as long as it can be used for food.
• 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol which is an active ingredient of the food additive of the present invention, Dispersibility for water-soluble food and drink is improved.
• the normal form of food additives such as a powder, a granule, a tablet, a liquid, can be taken.
• the food additive of the present invention contains the above-mentioned emulsifier, it is particularly preferable that the food additive is in an emulsifier form.
• the food additive of the present invention comprises 3-O- ⁇ -D-glucopyranosyl-4-methylergosto-7-en-3-ol as an active ingredient, and commonly used excipients, etc.
• the additive may be included.
• the well-known other component normally used for a food additive may be included.
• the food additive of the present invention can be produced by blending 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.
• the food additive of the present invention can be produced, for example, by formulating the active ingredient, preferably with the emulsifier, and optionally with the additive or other ingredients.
• the food additive of the present invention is a known plant containing 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as a raw material, and uses hot water or various solvents. It is also possible to produce an extract obtained by extraction, preferably with the above-mentioned emulsifier, and optionally with the above-mentioned additives and other components.
• the specific method for obtaining the extract is as exemplified in the section of “medicament of the present invention”.
• the food additive of the present invention can be used for producing the food and drink of the present invention described above.
• the amount added to the food and drink is based on the amount of 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient in the food and drink of the present invention described above. It can be adjusted as appropriate.
• the food additive of the present invention is in a form with indications of uses such as “for antioxidant”, “for inhibiting lipid oxidation”, and “for inhibiting lipid peroxide production”. “Display” and “display act” are as described in the section of “Food and Drink of the Present Invention”.
• the external preparation for skin of the present invention In the form using the antioxidant of the present invention as an external preparation for skin (referred to as “the external preparation for skin of the present invention”), treatment or improvement of skin conditions involving oxidation of biological components such as lipids, particularly formation of lipid peroxide. Can be used to prevent or prevent. For example, it can be used for pigmentation such as stains and freckles, dermatitis such as atopic dermatitis and acne, treatment or improvement or prevention of rough skin, improvement or prevention of wrinkles and decreased elasticity, hair loss and the like.
• the topical skin preparation includes those classified as pharmaceuticals, quasi drugs, and cosmetics.
• the external preparation for skin can be produced by blending a compound represented by the chemical formula (1) with a commonly known base. The method for extracting the compound and the like are as described in the “medicament of the present invention”.
• the present invention is a method for imparting antioxidant activity, preferably lipid oxidation inhibitory activity, more preferably lipid peroxide production inhibitory activity, to a food or drink, wherein the concentration of the compound represented by the chemical formula (1) in the food or drink is A step of blending the compound with food or drink so that the amount is at least 0.0001% by mass, preferably at least 0.001% by mass, more preferably at least 0.005% by mass, and particularly preferably at least 0.01% by mass.
• the definition of “food / beverage” is the same as the definition of food / beverage in the above-mentioned “food / beverage products of the present invention”.
• compound compounding in addition to compounding a purified or synthesized compound, the compound is concentrated by extraction with hot water or various solvents using a known plant containing the compound as a raw material. Including blended extracts is also included. The specific method for obtaining the extract is as exemplified in the section of “medicament of the present invention”.
• the present invention also relates to a method for enhancing the antioxidant activity, preferably the lipid oxidation inhibitory activity, more preferably lipid peroxide production inhibitory activity of a food or drink comprising the compound represented by the chemical formula (1),
• the concentration of the compound represented by the chemical formula (1) is at least 0.0001% by mass, preferably at least 0.001% by mass, more preferably at least 0.005% by mass, particularly preferably at least 0.01% by mass.
• a method comprising a step of blending the compound into a food or drink.
• the definition of “food / beverage product of the present invention” is also applied to the definition of “food / beverage product”.
• Examples of the food and drink containing the compound represented by the chemical formula (1) include food and drink containing an extract of a lily family plant.
• the food-drinks containing the flesh of an Aloe genus plant are mentioned.
• “compounding the compound” includes blending the purified or synthesized compound as well as blending the extract.
• the lipid peroxide production inhibitory action of various analytes containing the antioxidant of the present invention can be evaluated using, for example, the amount of thiobarbituric acid (TBA) -reactive substance (TBARS) as an index. Specifically, it can be defined that the larger the amount of TBARS, the more lipid peroxide is generated.
• TAA thiobarbituric acid
• TBARS thiobarbituric acid
• TBARS thiobarbituric acid
• TBARS thiobarbituric acid
• TBARS thiobarbituric acid
• TBARS thiobarbituric acid
• MDA malondialdehyde
• the MDA-TBA adduct can be detected by measuring the absorbance at 530 to 540 nm, whereby the MDA can be colorimetrically measured.
• the lipid peroxide production inhibitory effect of a subject can be evaluated using ApoE gene-deficient mice, which are often used as model animals that develop arteriosclerosis due to hypercholesterolemia (high LDL cholesterolemia).
• ApoE gene-deficient mice which are often used as model animals that develop arteriosclerosis due to hypercholesterolemia (high LDL cholesterolemia).
• Possible for example, Reference 1: “Cell Engineering”, separate volume “Medical Experiment Manual” series, “Arteriosclerosis + Hyperlipidemia Research Strategy", Shujunsha, 1st edition, 1st edition, April 1996 Issued 1 day, see pages 441-443). It is known that this model mouse does not exhibit obesity and develops cardiovascular disease from hyper-LDLemia to arteriosclerosis.
• lipid peroxide is increased in this model mouse as compared with normal mice, and formation of atherosclerotic lesions (plaque) in the artery is observed over time. Therefore, by administering a subject to a model mouse and measuring lipid peroxide in the blood of the model mouse, it is possible to evaluate the inhibitory effect of the subject on lipid peroxide production. Furthermore, since it is generally known that the initial lesion of arteriosclerosis is caused by oxidized LDL, by measuring the number of atherosclerotic plaques (plaques) in the artery of the model mouse administered the subject, It is also possible to evaluate the effect of the subject to reduce the risk of arteriosclerosis by suppressing lipid peroxide production.
• the ethyl acetate / butanol mixed solution and the aqueous layer were separated to recover the ethyl acetate / butanol mixed solution.
• the ethyl acetate / butanol mixed solution was concentrated under reduced pressure to obtain 13.5 g of an ethyl acetate / butanol mixed solution extract.
• a solution prepared by dissolving 13 g of the extract in 1 ml of a chloroform / methanol mixed solution (1: 1) was passed through a column packed with 400 g of silica gel 60 (manufactured by Merck) and adsorbed on the column, and then mixed with chloroform / methanol.
• a fraction eluted with chloroform: methanol 5: 1 was dissolved in 1 ml of a chloroform / methanol mixture (1: 1), and the column was packed with 180 g of Cosmo Seal 140 (manufactured by Nacalai Tesque). After flowing and adsorbing on the column, elution was successively performed with methanol 85% solution, 600 ml, methanol 95% solution, 600 ml, methanol 100%, 100 ml.
• 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol is concentrated and separated into an elution fraction of 95% methanol, and the solvent in the fraction is removed to obtain 370 mg of 3- O- ⁇ -D-glucopyranosyl-4-methylergosto-7-en-3-ol was obtained.
• the structure of the compound was confirmed by MS and NMR.
• Example 1 Using the ApoE gene-deficient mouse, a model animal that develops arteriosclerosis, we investigated the inhibitory effect of 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol on lipid peroxide production. .
• mice Male ApoE-deficient mice (purchased from Japan SLC), 6 weeks old, were preliminarily raised for 2 weeks using a high-cholesterol diet (manufactured by Research Diet), and then divided into 15 groups per group. did. Each group of mice was orally administered once a day for 3 consecutive days with 1 ml of each test sample, control sample, and negative sample solution per 25 g of mouse weight using a sonde. After the start of administration (14 days after the start of administration), blood is collected from each mouse's tail vein and separated into serum, and then the amount of TBARS is determined using the OxiSelect TBARS Assay Kit (manufactured by MDA Quantitation). It was measured. In addition, blood was collected from normal mice as a comparison target.
• Test result The test result of a present Example is as showing in Table 1.
• Table 1 shows the amount of lipid peroxide in blood (concentration of MDA in serum) when a sample of 30 ⁇ g per day was administered per mouse.
• mice treated with the negative sample a tendency to increase lipid peroxide in blood was observed compared to normal mice, but in the model mice that were administered the test sample continuously, production of lipid peroxide in blood was clearly observed.
• the inhibitory effect (significantly different, “*” in the table) was confirmed.
• 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol has a lipid peroxide production inhibitory effect and is effective in preventing or treating arteriosclerosis. It was confirmed that there was.
• Example 2 measures the number of atherosclerotic lesions (plaques) in an artery using an ApoE-deficient mouse known as an arteriosclerosis model animal, and reduces the risk of arteriosclerosis due to lipid peroxide suppression effect was evaluated for 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol.
• (1) Preparation of sample A test sample, a control sample, and a negative sample were prepared in the same manner as in Example 1, and each sample was used for the test.
• mice Male ApoE-deficient mice (purchased from Japan SLC), 6 weeks old, were preliminarily raised for 2 weeks using a high-cholesterol diet (manufactured by Research Diet), and then divided into 15 groups per group. did. Each group of mice was orally administered daily for 39 days using a sonde once a day for each sample solution of a test sample, a control sample, and a negative sample, each 1 ml per 25 g of mouse body weight. On the 40th day from the start of administration, the thoracic aorta was fixed in formalin, and the number of plaques was measured by oil red staining.
• Test result The test result of a present Example is as showing in Table 2.
• Table 2 shows the number of atherosclerotic lesions (plaques) in the artery of the model mouse to which each sample solution was administered.
• the number of plaques was 12.2
• the number of plaques was halved to 5.8.
• the effect of suppressing plaque formation was confirmed (there is a significant difference, “*” in the table).
• mevalotin although plaque formation was reduced as compared with the negative sample, no significant difference was observed. During and after the administration period, no side effects were observed from the body weight and pathological findings of the mice.
• 3-O- ⁇ -D-glucopyranosyl-4-methylergost-7-en-3-ol has an inhibitory effect on the formation of plaque in blood vessels, and the risk of arteriosclerosis due to the lipid peroxide inhibitory effect. It became clear to reduce.
• the antioxidant of the present invention can be safely administered, suppresses the oxidation of biological components, and particularly effectively suppresses the production of lipid peroxide in the blood. Therefore, arteriosclerosis, stroke, angina pectoris, myocardium It is effective for treatment and / or prevention of diseases and symptoms such as infarction, liver dysfunction, cirrhosis, hepatitis, retinopathy, cataract, Alzheimer's disease, Parkinson's disease, allergic disease, cancer, rough skin, and aging. Among them, the antioxidant of the present invention is highly effective for the treatment and / or prevention of arteriosclerosis, angina pectoris, and myocardial infarction. Therefore, the medicament of the present invention is useful for the treatment and prevention of the above diseases and symptoms.
• the food and drink of the present invention can be safely ingested, and effectively suppresses the formation of lipid peroxide in the living body, particularly in blood. Useful to do.
• the food additive of this invention is useful in manufacturing such food / beverage products, or preventing the oxidation of the component in food / beverage products.
• the external preparation for skin of the present invention is useful for the treatment or improvement of pigmentation such as stains and freckles, atopic dermatitis, acne and other dermatitis, or prevention or improvement or prevention of wrinkles and elasticity, hair loss, etc. It is.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Ophthalmology & Optometry (AREA)
• Mycology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Biochemistry (AREA)
• Toxicology (AREA)
• Urology & Nephrology (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Psychology (AREA)
• Vascular Medicine (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=42198233

Family Applications (1)

Country Status (9)

Cited By (2)

Families Citing this family (3)

Citations (6)

Family Cites Families (27)

• 2009
  • 2009-11-18 WO PCT/JP2009/069562 patent/WO2010058794A1/ja active Application Filing
  • 2009-11-18 KR KR1020137022377A patent/KR101434129B1/ko active IP Right Grant
  • 2009-11-18 CA CA2742946A patent/CA2742946C/en active Active
  • 2009-11-18 EP EP09827575.3A patent/EP2377875B1/en active Active
  • 2009-11-18 AU AU2009318455A patent/AU2009318455B2/en active Active
  • 2009-11-18 RU RU2011124912/15A patent/RU2465909C1/ru not_active IP Right Cessation
  • 2009-11-18 US US13/127,688 patent/US8486899B2/en active Active
  • 2009-11-18 JP JP2010511409A patent/JP4580041B2/ja active Active
  • 2009-11-18 CN CN2009801468035A patent/CN102216318B/zh active Active
  • 2009-11-18 KR KR1020117010882A patent/KR101331772B1/ko active IP Right Grant

Patent Citations (6)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events